Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of BGG492 in Partial Onset Seizures
NCT01338805Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2011
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of selurampanel in focal onset seizure, sponsored by Novartis. Started Jun 2011; status: completed.
02
Drugs
selurampanel
03
Conditions
focal onset seizure
Beyond the preview
Go deeper on NCT01338805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01338805.